B+
Bull case
25%
Probability
Target price
$3.80
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
TMCI
Treace Medical ConceptsFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The constructive setup is that Treace has already cut cash usage materially, guided to another roughly 50% reduction in 2026 cash usage, posted a preliminary Q1 cash increase, and now has identifiable launch hooks in SuperBite and SpeedXM that could improve surgeon wallet share if execution is clean. [#8-K-2026-04-09] [#PR-2026-04-07]
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Commercial execution risk increased after the April 8, 2026 chief commercial officer departure disclosed in the 8-K.
Momentum
88
Value
37
Sentiment
6
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.20 · Bull $3.80 · Bear $1.30Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $5.50
Why
Momentum88 · Δ7d -2.5
Value37 · Δ7d -0.0
Sentiment6 · Δ7d +3.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Commercial execution risk increased after the April 8, 2026 chief commercial officer departure disclosed in the 8-K.
- • Competitive pressure in bunion and minimally invasive osteotomy markets could limit surgeon adoption gains or force pricing concessions.
- • The bear case is that the core business still looks fragile: Q4 2025 revenue fell 9% year over year, full-year 2026 guidance was only $200-$212 million, management explicitly cited lower-priced kit mix and competitive/minimally invasive pressure, and preliminary Q1 2026 revenue is below Q1 2025’s $52.6 million.
Catalyst clock
2026-07-14
Q1 2026 final print must validate preliminary revenue and cash improvement
Lead driver: Value · See fundamentals
Momentum
88
9% active weight
Current posture
7d trendSoftening
Δ7d
-2.5
Δ21d
-0.7
Value
37
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
6
62% active weight
Current posture
7d trendImproving
Δ7d
+3.6
Δ21d
+2.5
Why this grade
Composite grade F. Momentum 87.8 / Value 36.6 / Sentiment 5.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.30
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$292.66M
Beta
0.74
Shares Out
65.03M
P/E (TTM) · Derived
-4.8
P/S (TTM)
0.77
P/FCF (TTM) · Derived
-11.48
Rev YoY
-4.2%
EPS YoY
-11.6%
Gross Margin
+79.5%
Op Margin
-26.2%
Net Debt
$23.5M
Current Ratio
2.90
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data